Prognostic significance and targeting of HER family in colorectal cancer

Frontiers in Bioscience

Volumn 18, Issue 2, 2013, Pages 394-421

  Khelwatty, Said Abdullah ^a   Essapen, Sharadah ^b   Seddon, Alan Michael ^a   Modjtahedi, Helmout ^a  

^a KINGSTON UNIVERSITY   (United Kingdom)

^b Royal Surrey County Hospital NHS Trust   (United Kingdom)

Author keywords

Colorectal Cancer; EGFR; HER 2; HER 3; HER 4; Monoclonal Antibody; Review; Small Molecule Tyrosine Kinsase

Indexed keywords

BEVACIZUMAB; CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR 3; GEFITINIB; IMC 11F8 MONOCLONAL ANTIBODY; IMC-11F8 MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY; PANITUMUMAB; PROTEIN TYROSINE KINASE; QUINAZOLINE DERIVATIVE; RECEPTOR TYROSINE PROTEIN KINASE ERBB 4; RECEPTOR TYROSINE-PROTEIN KINASE ERBB-4; VASCULOTROPIN A;

COLORECTAL TUMOR; DRUG ANTAGONISM; DRUG EFFECT; HUMAN; METASTASIS; PATHOPHYSIOLOGY; PROGNOSIS; REVIEW; SIGNAL TRANSDUCTION;

ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; COLORECTAL NEOPLASMS; HUMANS; PROGNOSIS; QUINAZOLINES; RECEPTOR PROTEIN-TYROSINE KINASES; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; RECEPTOR, ERBB-3; SIGNAL TRANSDUCTION; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

MLCS; MLOWN;

EID: 84878784424     PISSN: 27686701     EISSN: 27686698     Source Type: Journal    
DOI: 10.2741/4110     Document Type: Article

References (238)

1. Ferlay, J., H. R. Shin, F. Bray, D. Forman, C. Mathers & D. M. Parkin: Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. International Journal of Cancer2893-2917 (2010)
2. Center, M. M., A. Jemal, R. A. Smith & E. Ward: Worldwide Variations in Colorectal Cancer. CA Cancer J Clin, 59, 366-378 (2009)
3. Siegel, R., D. Naishadham & A. Jemal: Cancer statistics, 2012. CA: A Cancer Journal for Clinicians, 62, 10-29 (2012)
4. Walker, J. & P. Quirke: Prognosis and response to therapy in colorectal cancer. Eur J Cancer, 38, 880-886 (2002) (Pubitemid 34442315)
5. Jemal, A., R. Siegel, J. Xu & E. Ward: Cancer Statistics, 2010. CA: A Cancer Journal for Clinicians, 60, 277-300 (2010)
6. Iqbal, S. & H.-J. Lenz: Integration of novel agents in the treatment of colorectal cancer. Cancer Chemotherapy & Pharmacology, 54, S32-S39 (2004) (Pubitemid 39517746)
7. Hamilton, S. R.: Targeted therapy of cancer: new roles for pathologists in colorectal cancer. Mod Pathol, 21, S23- S30 (2008) (Pubitemid 351592774)
8. Mason, P.: Colorectal cancer: the disease and its management. Hospital Pharmacist, 11, 175-177 (2004) (Pubitemid 38639417)
9. Wong, S.: Cetuximab: An Epidermal Growth Factor Receptor Monoclonal Antibody for the Treatment of colorectal cancer. Clinical Therapeutics, 27, 684-694 (2005) (Pubitemid 41583517)
10. Wu, M., A. Rivkin & T. Pham: Panitumumab:Human monoclonal antibody against epidermal growth factor receptor for the treatment of metastatic colorectal cancer. Clinical Therapeutics, 30, 14-29 (2008)
11. Shih, T. & C. Lindley: Bevacizumab: an angiogenesis inhibitor for the treatment of solid malignancies. Clinical Therapeutics, 28, 1779-802 (2006) (Pubitemid 46038527)
12. Chu, E.: An update on the current and emerging targeted agents in metastatic colorectal cancer. Clinical Colorectal Cancer, 11, 1-13 (2012)
13. Gullick, W. G.: Prevalence of aberant expression of the epidermal growth factor receptor in human cancers. Br Med Bull, 47, 87-98 (1991)
14. Yarden, Y.: The EGFR family and its ligands in human cancer: signalling mechanisms and therapeutic opportunities. European Journal of Cancer, 37, 3-8 (2001)
15. Lemmon, M. A. & J. Schlessinger: Cell signaling by receptor tyrosine kinases. Cell, 141, 1117-34 (2010)
16. Gullick, W.: The Type 1 growth factor receptors and their ligands considered as a complex system. Endocr Relat Cancer, 8, 75-82 (2001) (Pubitemid 32641350)
17. Singh, A. B. & R. C. Harris: Autocrine, paracrine and juxtacrine signaling by EGFR ligands. Cellular Signalling, 17, 1183-93 (2005) (Pubitemid 40984037)
18. Burgess, A. W.: EGFR family: structure physiology signalling and therapeutic targets. Growth Factors, 26, 263- 74 (2008)
19. Laurent-Puig, P., A. Cayre, G. Manceau, E. Buc, J.-B. Bachet, T. Lecomte, P. Rougier, A. Lievre, B. Landi, V. Boige, M. Ducreux, M. Ychou, F. Bibeau, O. Bouche, J. Reid, S. Stone & F. Penault-Llorca: Analysis of PTEN, BRAF, and EGFR Status in Determining Benefit From Cetuximab Therapy in Wild-Type KRAS Metastatic Colon Cancer. J Clin Oncol, 27, 5924-5930 (2009)
20. Anklesaria, P., J. Teixidó, M. Laiho, J. H. Pierce, J. S. Greenberger & J. Massagué: Cell-cell adhesion mediated by binding of membrane-anchored transforming growth factor alpha to epidermal growth factor receptors promotes cell proliferation. Proceedings of the National Academy of Sciences of the United States of America, 87, 3289-3293 (1990)
21. Dent, P., D. B. Reardon, J. S. Park, G. Bowers, C. Logsdon, K. Valerie & R. Schmidt-Ullrich: Radiationinduced release of transforming growth factor alpha activates the epidermal growth factor receptor and mitogenactivated protein kinase pathway in carcinoma cells, leading to increased proliferation and protection from radiation-induced cell death. Mol Biol Cell, 10, 2493-506 (1999) (Pubitemid 29393505)
22. Giralt, J., A. Eraso, M. Armengol, J. Rossello, J. Majo, C. Ares, E. Espin, S. Benavente & I. de Torres: Epidermal growth factor receptor is a predictor of tumor response in locally advanced rectal cancer patients treated with preoperative radiotherapy. Int J Radiat Oncol Biol Phys, 54, 1460-5 (2002)
23. Mendelsohn, J. & J. Baselga: Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer. J Clin Oncol, 21, 2787-99 (2003) (Pubitemid 46606324)
24. Herbst, R. S.: Review of epidermal growth factor receptor biology. Int J Radiat Oncol Biol Phys, 59, 21-6 (2004) (Pubitemid 38610223)
25. Hanahan, D. & R. A. Weinberg: Hallmarks of cancer: the next generation. Cell, 144, 646-74 (2011)
26. Zhang, H., A. Berezov, Q. Wang, G. Zhang, J. Drebin, R. Murali & M. I. Greene: ErbB receptors: from oncogenes to targeted cancer therapies. The Journal of Clinical Investigation, 117, 2051-2058 (2007) (Pubitemid 47224766)
27. Modjtahedi, H. & C. Dean: The receptor for EGF and its ligands: expression, prognostic value, and target for therapy in cancer. Int J Onco, 4, 277-296 (1994) (Pubitemid 24039840)
28. Nicholson, R. I., J. W. Gee & M. E. Harper: EGFR and cancer prognosis. Eur J Cancer, 37, 9-15 (2001)
29. Baselga, J. & C. L. Arteaga: Critical update and emerging trends in epidermal growth factor receptor targeting in cancer. Journal of Clinical Oncology, 23, 2445-59 (2005) (Pubitemid 47050835)
30. Zandi, R., A. B. Larsen, P. Andersen, M. T. Stockhausen & H. S. Poulsen: Mechanisms for oncogenic activation of the epidermal growth factor receptor. Cellular Signalling, 19, 2013-23 (2007) (Pubitemid 47353811)
31. Bhola, N. E. & J. R. Grandis: Crosstalk between Gprotein- coupled receptors and epidermal growth factor receptor in cancer. Frontiers in Bioscience, 13, 1857-65 (2008) (Pubitemid 351599738)
32. Hu, Y. P., S. B. Patil, M. Panasiewicz, W. Li, J. Hauser, L. E. Humphrey & M. G. Brattain: Heterogeneity of Receptor Function in Colon Carcinoma Cells Determined by Cross-talk between Type I Insulinlike Growth Factor Receptor and Epidermal Growth Factor Receptor. Cancer Res, 68, 8004-8013 (2008)
33. Modjtahedi, H. & S. Essapen: Epidermal growth factor receptor inhibitors in cancer treatment: advances, challenges and opportunities. Anticancer Drugs., 20, 851-5. (2009)
34. Lu, Y., X. Zi, Y. Zhao, D. Mascarenhas & M. Pollak: Insulin-like growth factor-I receptor signaling and resistance to trastuzumab (Herceptin). Journal of the National Cancer Institute, 93, 1852-7 (2001)
35. Adams, T. E., N. M. McKern & C. W. Ward: Signalling by the type 1 insulin-like growth factor receptor: interplay with the epidermal growth factor receptor. Growth Factors, 22, 89-95 (2004) (Pubitemid 38923312)
36. Grossmann, A. H. & W. S. Samowitz: Epidermal Growth Factor Receptor Pathway Mutations and Colorectal Cancer Therapy. Archives of Pathology & Laboratory Medicine, 135, 1278-1282 (2011)
37. Lin, S. Y., K. Makino, W. Xia, A. Matin, Y. Wen, K. Y. Kwong, L. Bourguignon & M. C. Hung: Nuclear localization of EGF receptor and its potential new role as a transcription factor. Nature Cell Biology, 3, 802-8 (2001) (Pubitemid 32842685)
38. Lo, H.-W., S.-C. Hsu & M.-C. Hung: EGFR signaling pathway in breast cancers: from traditional signal transduction to direct nuclear translocalization. Breast Cancer Research & Treatment, 95, 211-218 (2006)
39. Dittmann, K., C. Mayer & P. H. Rodemann: Nuclear EGFR as novel therapeutic target. Strahlenther Onkologie, 186, 1-6 (2010)
40. Dekanic, A., R. D. Dintinjan, I. Budisavljevic, S. Pecanic, M. Z. Butorac & N. Jonjic: Strong nuclear EGFR expression in colorectal carcinomas is associated with cyclin-D1 but not with gene EGFR amplification. Diagnostic Pathology, 6, 108 (2011)
41. Hsu, S. C., S. A. Miller, Y. Wang & M. C. Hung: Nuclear EGFR is required for cisplatin resistance and DNA repair. American Journal of Translational Research, 1, 249-58 (2009)
42. Hadzisejdic, I., E. Mustac, N. Jonjic, M. Petkovic & B. Grahovac: Nuclear EGFR in ductal invasive breast cancer: correlation with cyclin-D1 and prognosis. Modern Pathology, 23, 392-403 (2010)
43. Liccardi, G., J. A. Hartley & D. Hochhauser: EGFR nuclear translocation modulates DNA repair following cisplatin and ionizing radiation treatment. Cancer Research, 71, 1103-14 (2011)
44. Brand, T. M., M. Iida, C. Li & D. L. Wheeler: The nuclear epidermal growth factor receptor signaling network and its role in cancer. Discovery Medicine, 12, 419-32 (2011)
45. Xia, W., Z. Liu, R. Zong, L. Liu, S. Zhao, S. S. Bacus, Y. Mao, J. He, J. D. Wulfkuhle, E. F. Petricoin, 3rd, T. Osada, X. Y. Yang, Z. C. Hartman, T. M. Clay, K. L. Blackwell, H. K. Lyerly & N. L. Spector: Truncated ErbB2 expressed in tumor cell nuclei contributes to acquired therapeutic resistance to ErbB2 kinase inhibitors. Molecular Cancer Therapeutics, 10, 1367-74 (2011)
46. Li, C., M. Iida, E. F. Dunn, A. J. Ghia & D. L. Wheeler: Nuclear EGFR contributes to acquired resistance to cetuximab. Oncogene, 28, 3801-3813 (2009)
47. Huang, W.-C., Y.-J. Chen & M.-C. Hung: Implication of nuclear EGFR in the development of resistance to anticancer therapies. Biomedicine, 1, 2-10 (2011)
48. Ooi, A., T. Takehana, X. Li, S. Suzuki, K. Kunitomo, H. Iino, H. Fujii, Y. Takeda & Y. Dobashi: Protein overexpression and gene amplification of HER-2 and EGFR in colorectal cancers: an immunohistochemical and fluorescent in situ hybridization study. Mod Pathol, 17, 895-904 (2004) (Pubitemid 38993773)
49. Spano, J.-P., C. Lagorce, D. Atlan, G. Milano, J. Domont, R. Benamouzig, A. Attar, J. Benichou, A. Martin, J.-F. Morere, M. Raphael, F. Penault-Llorca, J.-L. Breau, R. Fagard, D. Khayat & P. Wind: Impact of EGFR expression on colorectal cancer patient prognosis and survival. Ann Oncol, 16, 102-108 (2005) (Pubitemid 40124486)
50. Frattini, M., P. Saletti, E. Romagnani, V. Martin, F. Molinari, M. Ghisletta, A. Camponovo, L. L. Etienne, F. Cavalli & L. Mazzucchelli: PTEN loss of expression predicts cetuximab efficacy in metastatic colorectal cancer patients. Br J Cancer, 97, 1139-1145 (2007) (Pubitemid 47587019)
51. Mayer, A., M. Takimoto, E. Fritz, G. Schellander, K. Kofler & H. Ludwig: The prognostic significance of proliferating cell nuclear antigen, epidermal growth factor receptor, and mdr gene expression in colorectal cancer. Cancer, 71, 2454-2460 (1993) (Pubitemid 23100476)
52. Khambata-Ford, S., C. R. Garrett, N. J. Meropol, M. Basik, C. T. Harbison, S. Wu, T. W. Wong, X. Huang, C. H. Takimoto, A. K. Godwin, B. R. Tan, S. S. Krishnamurthi, H. A. Burris, III, E. A. Poplin, M. Hidalgo, J. Baselga, E. A. Clark & D. J. Mauro: Expression of Epiregulin and Amphiregulin and K-ras Mutation Status Predict Disease Control in Metastatic Colorectal Cancer Patients Treated With Cetuximab. J Clin Oncol, 25, 3230- 3237 (2007) (Pubitemid 47325606)
53. Campanella, C., M. Mottolese, A. Cianciulli, A. Torsello, R. Merola, I. Sperduti, E. Melucci, S. Conti, M. G. Diodoro, M. Zeuli, G. Paoletti, F. Cognetti & C. Garufi: Epidermal growth factor receptor gene copy number in 101 advanced colorectal cancer patients treated with chemotherapy plus cetuximab. J Transl Med, 8, 36 (2010)
54. Shia, J., D. S. Klimstra, A. R. Li, J. Qin, L. Saltz, J. Teruya-Feldstein, M. Akram, K. Y. Chung, D. Yao, P. B. Paty, W. Gerald & B. Chen: Epidermal growth factor receptor expression and gene amplification in colorectal carcinoma: an immunohistochemical and chromogenic in situ hybridization study. Mod Pathol, 18, 1350-1356 (2005) (Pubitemid 41348654)
55. Jolien, T., R. D. Jeroen, K. Marjolein, T. Steven, D. Martin, M. E. Vink-Börger, H. v. C. Patricia, J. H. v. Krieken, J. A. P. Cornelis & D. N. Iris: Markers for EGFR pathway activation as predictor of outcome in metastatic colorectal cancer patients treated with or without cetuximab. European journal of cancer (Oxford, England : 1990), 46, 1997-2009 (2010)
56. Modjtahedi, H., S. A. Khelwatty, R. S. Kirk, A. M. Seddon, S. Essapen, C. A. Del Vecchio, A. J. Wong & S. Eccles: Immunohistochemical discrimination of wild-type EGFR from EGFRvIII in fixed tumour specimens using anti-EGFR mAbs ICR9 and ICR10. British Journal of Cancer, 106, 883-888 (2012)
57. Tos, A. P. D. & I. Ellis: Assessing epidermal growth factor receptor expression in tumours: What is the value of current test methods? European journal of cancer (Oxford, England : 1990), 41, 1383-1392 (2005) (Pubitemid 40826461)
58. Kluftinger, A. M., B. W. Robinson, N. F. Quenville, R. J. Finley & N. L. Davis: Correlation of epidermal growth factor receptor and c-erbB2 oncogene product to known prognostic indicators of colorectal cancer. Surgical Oncology, 1, 97-105 (1992)
59. Galizia, G., E. Lieto, F. Ferraraccio, F. De Vita, P. Castellano, M. Orditura, V. Imperatore, A. Mura, G. Manna, M. Pinto, G. Catalano, C. Pignatelli & F. Ciardiello: Prognostic Significance of Epidermal Growth Factor Receptor Expression in Colon Cancer Patients Undergoing Curative Surgery. Annals of Surgical Oncology, 13, 823-835 (2006) (Pubitemid 43727367)
60. Ljuslinder, I., B. Melin, M. L. Henriksson, A. Oberg & R. Palmqvist: Increased epidermal growth factor receptor expression at the invasive margin is a negative prognostic factor in colorectal cancer. International Journal of Cancer, 128, 2031-7 (2011)
61. Scartozzi, M., I. Bearzi, R. Berardi, A. Mandolesi, G. Fabris & S. Cascinu: Epidermal growth factor receptor (EGFR) status in primary colorectal tumors does not correlate with EGFR expression in related metastatic sites: Implications for treatment with EGFR-Targeted Monocolonal Antibodies. Journal of clinical oncology, 22, 4772-4778 (2004)
62. Cunningham, M. P., S. Essapen, H. Thomas, M. Green, D. P. Lovell, C. Topham, C. Marks & H. Modjtahedi: Coexpression of the IGF-IR, EGFR and HER-2 is common in colorectal cancer patients. International Journal of Oncology, 28, 329-335 (2006)
63. Takemura, K., T. Obara, S. Okano, K. Yokota, H. Ura, Y. Saitoh, Y. Koike, K. Okamura & M. Namiki: Immunohistochemical study on the expression of epidermal growth factor receptor (EGFR) in human colorectal carcinomas. Nihon Shokakibyo Gakkai Zasshi, 88, 1177-83 (1991)
64. Baiocchi, G., A. Lopes, R. Coudry, B. Rossi, F. Soares, S. Aguiar, G. Guimarães, F. Ferreira & W. Nakagawa: ErbB family immunohistochemical expression in colorectal cancer patients with higher risk of recurrence after radical surgery. International Journal of Colorectal Disease, 24, 1059-1068 (2009)
65. McKay, J. A., L. J. Murray, S. Curran, V. G. Ross, C. Clark, G. I. Murray, J. Cassidy & H. L. McLeod: Evaluation of the epidermal growth factor receptor (EGFR) in colorectal tumours and lymph node metastases. European Journal of Cancer, 38, 2258-2264 (2002) (Pubitemid 35346467)
66. Yamada, M., Y. Ichikawa, S. Yamagishi, N. Momiyama, M. Ota, S. Fujii, K. Tanaka, S. Togo, S. Ohki & H. Shimada: Amphiregulin Is a Promising Prognostic Marker for Liver Metastases of Colorectal Cancer. Clinical Cancer Research, 14, 2351-2356 (2008) (Pubitemid 351551067)
67. Kuramochi, H., G. Nakajima, Y. Kaneko, A. Nakamura, Y. Inoue, M. Yamamoto & K. Hayashi: Amphiregulin and Epiregulin mRNA expression in primary colorectal cancer and corresponding liver metastases. BMC Cancer, 12, 88 (2012)
68. Baron, A. T., J. A. Wilken, D. E. Haggstrom, S. T. Goodrich & N. J. Maihle: Clinical implementation of soluble EGFR (sEGFR) as a theragnostic serum biomarker of breast, lung and ovarian cancer. IDrugs, 12, 302-8 (2009)
69. Cunningham, M. P., S. Essapen, H. Thomas, M. Green, D. P. Lovell, C. Topham, C. Marks & H. Modjtahedi: Coexpression, prognostic significance and predictive value of EGFR, EGFRvIII and phosphorylated EGFR in colorectal cancer. International Journal of Oncology, 27, 317-25 (2005)
70. Meropol, N. J.: Epidermal growth factor receptor inhibitors in colorectal cancer: it's time to get back on target. Journal of Clinical Oncology, 23, 1791-3 (2005)
71. Rego, R. L., N. R. Foster, T. C. Smyrk, M. Le, M. J. O'Connell, D. J. Sargent, H. Windschitl & F. A. Sinicrope: Prognostic effect of activated EGFR expression in human colon carcinomas: comparison with EGFR status. British Journal of Cancer, 102, 165-172 (2010)
72. Slamon, D., G. Clark, S. Wong, W. Levin, A. Ullrich & W. McGuire: Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science, 9;235, 177 - 82 (1987) (Pubitemid 17231334)
73. Mukai, H.: Targeted Therapy in Breast Cancer: Current Status and Future Directions. Jpn. J. Clin. Oncol.hyq037 (2010)
74. Ross, J. & B. McKenna: The HER-2/neu oncogene in tumors of the gastrointestinal tract. Cancer Investigation, 19, 554-568 (2001) (Pubitemid 32619394)
75. Al-Kuraya, K., H. Novotny, P. Bavi, A. K. Siraj, S. Uddin, A. Ezzat, N. A. Sanea, F. Al-Dayel, H. Al-Mana, S. S. Sheikh, M. Mirlacher, C. Tapia, R. Simon, G. Sauter, L. Terracciano & L. Tornillo: HER2, TOP2A, CCND1, EGFR and C-MYC oncogene amplification in colorectal cancer. Journal of Clinical Pathology, 60, 768-772 (2007) (Pubitemid 47056905)
76. Park, D., M. Kang, S. Oh, H. Kim, Y. Cho, C. Sohn, W. Jeon, B. Kim, W. Han, H. Kim, S. Ryu & A. Sepulveda: HER-2/neu overexpression is an independent prognostic factor in colorectal cancer. International Journal of Colorectal Disease, 22, 491-497 (2007) (Pubitemid 46488053)
77. Osako, T., M. Miyahara, S. Uchino, M. Inomata, S. Kitano & M. Kobayashi: Immunohistochemical Study of cerbB- 2 Protein in Colorectal Cancer and the Correlation with Patient Survival. Oncology, 55, 548-555 (1998) (Pubitemid 28479114)
78. Kruszewski, W. J., R. Rzepko, M. Ciesielski, J. Szefel, J. Zielinski, M. Szajewski, W. Jasinski, K. Kawecki & J. Wojtacki: Expression of HER2 in colorectal cancer does not correlate with prognosis. Disease Markers, 29, 207-12 (2010)
79. Kavanagh, D., G. Chambers, L. O' Grady, K. Barry, R. Waldron, F. Bennani, P. Eustace & I. Tobbia: Is overexpression of HER-2 a predictor of prognosis in colorectal cancer? BMC Cancer, 9, 1 (2009)
80. Wei, Q., Y. Shui, S. Zheng, K. Wester, H. Nordgren, P. Nygren, B. Glimelius & J. Carlsson: EGFR, HER2 and HER3 expression in primary colorectal carcinomas and corresponding metastases: Implications for targeted radionuclide therapy. Oncology Reports, 25, 3-11 (2011)
81. Essapen, S., H. Thomas, M. Green, C. De Vries, M. Cook, C. Marks, C. Topham & H. Modjtahedi: The expression and prognostic significance of HER-2 in CRC. Int J Oncol, 24, 241 - 8 (2004)
82. Schuell, B., T. Gruenberger, W. Scheithauer, C. Zielinski & F. Wrba: Her-2/neu protein expression in colorectal cancer. BMC Cancer, 6, 123 (2006)
83. Antonacopoulou, A. G., A. C. Tsamandas, T. Petsas, A. Liava, C. D. Scopa, A. G. Papavassiliou & H. P. Kalofonos: EGFR, HER-2 and COX-2 levels in colorectal cancer. Histopathology, 53, 698-706 (2008) (Pubitemid 352768714)
84. Rajkumar, T., C. S. Gooden, N. R. Lemoine, W. J. Gullick & C. S. Goden: Expression of the c-erbB-3 protein in gastrointestinal tract tumours determined by monoclonal antibody RTJ1. Journal of Pathology, 170, 271-8 (1993) (Pubitemid 23234874)
85. Kountourakis, P., K. Pavlakis, A. Psyrri, D. Rontogianni, N. Xiros, E. Patsouris, D. Pectasides & T. Economopoulos: Prognostic significance of HER3 and HER4 protein expression in colorectal adenocarcinomas. BMC Cancer, 6, 46 (2006)
86. Grivas, P. D., A. Antonacopoulou, V. Tzelepi, G. Sotiropoulou-Bonikou, Z. Kefalopoulou, A. G. Papavassiliou & H. Kalofonos: HER-3 in colorectal tumourigenesis: From mRNA levels through protein status to clinicopathologic relationships. European Journal of Cancer, 43, 2602-2611 (2007) (Pubitemid 350103546)
87. Amin, D. N., M. R. Campbell & M. M. Moasser: The role of HER3, the unpretentious member of the HER family, in cancer biology and cancer therapeutics. Seminars in Cell & Developmental Biology, 21, 944-50 (2010)
88. Maurer, C. A., H. Friess, B. Kretschmann, A. Zimmermann, A. Stauffer, H. U. Baer, M. Korc & M. W. Buchler: Increased expression of erbB3 in colorectal cancer is associated with concomitant increase in the level of erbB2. Human Pathology, 29, 771-777 (1998) (Pubitemid 28375981)
89. Lee, J. C., S. T. Wang, N. H. Chow & H. B. Yang: Investigation of the prognostic value of coexpressed erbB family members for the survival of colorectal cancer patients after curative surgery. European Journal of Cancer, 38, 1065-1071 (2002) (Pubitemid 34468011)
90. Scartozzi, M., A. Mandolesi, R. Giampieri, A. Bittoni, C. Pierantoni, A. Zaniboni, E. Galizia, L. Giustini, R. R. Silva, R. Bisonni, R. Berardi, T. Biscotti, S. Biagetti, I. Bearzi & S. Cascinu: The Role of HER-3 Expression in the Prediction of Clinical Outcome for Advanced Colorectal Cancer Patients Receiving Irinotecan and Cetuximab. Oncologist, 16, 53-60 (2011)
91. Kapitanović, S., S. Radošević, N. Slade, M. Kapitanović, Š. Andelinović, Ž. Ferenč ić, M. Tavassoli, Š. Spaventi, K. Pavelić & R. Spaventi: Expression of erbB-3 protein in colorectal adenocarcinoma: correlation with poor survival. Journal of Cancer Research & Clinical Oncology, 126, 205-211 (2000) (Pubitemid 30183023)
92. Ljuslinder, I., B. Malmer, M. Isaksson-Mettävainio, Å. Öberg, R. Henriksson, R. Stenling & R. Palmqvist: ErbB 1- 4 expression alterations in primary colorectal cancers and their corresponding metastases. Anticancer Research, 29, 1489-1494 (2009).
93. Khelwatty, S. A., S. Essapen, A. M. Seddon & H. Modjtahedi: Growth response of human colorectal tumour cell lines to treatment with afatinib (BIBW2992), an irreversible erbB family blocker, and its association with expression of HER family members. International Journal of Oncology, 39, 483-491 (2011)
94. Cunningham, D., Y. Humblet, S. Siena, D. Khayat, H. Bleiberg, A. Santoro, D. Bets, M. Mueser, A. Harstrick, C. Verslype, I. Chau & E. Van Cutsem: Cetuximab Monotherapy and Cetuximab plus Irinotecan in Irinotecan- Refractory Metastatic Colorectal Cancer. N Engl J Med, 351, 337-345 (2004) (Pubitemid 38944402)
95. Chung, K. Y., J. Shia & N. E. Kemeny: Cetuximab shows activity in colorectal cancer patients with tumours that do not express the epidermal growth factor receptor by immunohistochemistry. J Clin Oncol, 23, 1803-10 (2005) (Pubitemid 46211358)
96. Lenz, H. J., E. Van Cutsem & S. Khambata-Ford: Multicenter phase II and translational study of cetuximab in metastatic colorectal carcinoma refractory to irinotecan, oxaliplatin, and fluoropyrimidines. J Clin Oncol, 24, 4914- 21 (2006) (Pubitemid 46630920)
97. Cappuzzo, F., M. Varella-Garcia, G. Finocchiaro, M. Skokan, S. Gajapathy, C. Carnaghi, L. Rimassa, E. Rossi, C. Ligorio, L. Di Tommaso, A. J. Holmes, L. Toschi, G. Tallini, A. Destro, M. Roncalli, A. Santoro & P. A. Janne: Primary resistance to cetuximab therapy in EGFR FISHpositive colorectal cancer patients. Br J Cancer, 99, 83-89 (2008) (Pubitemid 351920237)
98. Hebbar, M., M. Ychou & M. Ducreux: Current place of high-dose irinotecan chemotherapy in patients with metastatic colorectal cancer. Journal of Cancer Research & Clinical Oncology, 135, 749-752 (2009)
99. Moroni, M., S. Veronese, S. Benvenuti, G. Marrapese, A. Sartore-Bianchi, F. Di Nicolantonio, M. Gambacorta, S. Siena & A. Bardelli: Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study. The Lancet Oncology, 6, 279-286 (2005) (Pubitemid 40590264)
100. Sartore-Bianchi, A., M. Moroni, S. Veronese, C. Carnaghi, E. Bajetta, G. Luppi, A. Sobrero, C. Barone, S. Cascinu, G. Colucci, E. Cortesi, M. Nichelatti, M. Gambacorta & S. Siena: Epidermal Growth Factor Receptor Gene Copy Number and Clinical Outcome of Metastatic Colorectal Cancer Treated With Panitumumab. J Clin Oncol, 25, 3238-3245 (2007) (Pubitemid 47325607)
101. Messersmith, W. A., D. A. Laheru, N. N. Senzer, R. C. Donehower, P. Grouleff, T. Rogers, S. K. Kelley, D. A. Ramies, B. L. Lum & M. Hidalgo: Phase I Trial of Irinotecan, Infusional 5-Fluorouracil, and Leucovorin (FOLFIRI) with Erlotinib (OSI-774). Clinical Cancer Research, 10, 6522-6527 (2004)
102. Townsley, C. A., P. Major, L. L. Siu, J. Dancey, E. Chen, G. R. Pond, T. Nicklee, J. Ho, D. Hedley, M. Tsao, M. J. Moore & A. M. Oza: Phase II study of erlotinib (OSI- 774) in patients with metastatic colorectal cancer. Br J Cancer, 94, 1136-43 (2006)
103. Meyerhardt, J., K. Stuart, C. Fuchs, A. Zhu, C. Earle, P. Bhargava, L. Blaszkowsky, P. Enzinger, R. Mayer, S. Battu, C. Lawrence & D. Ryan: Phase II study of FOLFOX, bevacizumab and erlotinib as first-line therapy for patients with metastastic colorectal cancer. Ann Oncolmdm124 (2007)
104. Fan, Z., H. Masui, I. Altas & J. Mendelsohn: Blockade of epidermal growth factor receptor function by bivalent and monovalent fragments of 225 anti-epidermal growth factor receptor monoclonal antibodies. Cancer Research, 53, 4322-8 (1993)
105. Richman, S. D., M. T. Seymour, P. Chambers, F. Elliott, C. L. Daly, A. M. Meade, G. Taylor, J. H. Barrett & P. Quirke: KRAS and BRAF Mutations in Advanced Colorectal Cancer Are Associated With Poor Prognosis but Do Not Preclude Benefit From Oxaliplatin or Irinotecan: Results From the MRC FOCUS Trial. J Clin Oncol, 27, 5931-5937 (2009)
106. Folprecht, G., T. Gruenberger, W. O. Bechstein, H. R. Raab, F. Lordick, J. T. Hartmann, H. Lang, A. Frilling, J. Stoehlmacher, J. Weitz, R. Konopke, C. Stroszczynski, T. Liersch, D. Ockert, T. Herrmann, E. Goekkurt, F. Parisi & C. H. Kohne: Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial. Lancet Oncology, 11, 38-47 (2010)
107. Van Cutsem, E., M. Nowacki, I. Lang, S. Cascinu, I. Shchepotin, J. Maurel, P. Rougier, D. Cunningham, J. Nippgen & C. Kohne: Randomized phase III study of irinotecan and 5-FU/FA with or without cetuximab in the first-line treatment of patients with metastatic colorectal cancer (mCRC): The CRYSTAL trial. J Clin Oncol (Meeting Abstracts), 25, 4000- (2007)
108. Sobrero, A. F., J. Maurel, L. Fehrenbacher, W. Scheithauer, Y. A. Abubakr, M. P. Lutz, M. E. Vega- Villegas, C. Eng, E. U. Steinhauer, J. Prausova, H.-J. Lenz, C. Borg, G. Middleton, H. Kroning, G. Luppi, O. Kisker, A. Zubel, C. Langer, J. Kopit & H. A. Burris, III: EPIC: Phase III Trial of Cetuximab Plus Irinotecan After Fluoropyrimidine and Oxaliplatin Failure in Patients With Metastatic Colorectal Cancer. J Clin Oncol, 26, 2311-2319 (2008)
109. Keating, G. M.: Panitumumab: a review of its use in metastatic colorectal cancer. Drugs, 70, 1059-78 (2010)
110. Gravalos, C., J. Cassinello, P. Garcia-Alfonso & A. Jimeno: Integration of panitumumab into the treatment of colorectal cancer. Critical Reviews in Oncology/Hematology, 74, 16-26 (2010)
111. Van Cutsem, E., M. Peeters, S. Siena, Y. Humblet, A. Hendlisz, B. Neyns, J.-L. Canon, J.-L. Van Laethem, J. Maurel, G. Richardson, M. Wolf & R. G. Amado: Open-Label Phase III Trial of Panitumumab Plus Best Supportive Care Compared With Best Supportive Care Alone in Patients With Chemotherapy- Refractory Metastatic Colorectal Cancer. J Clin Oncol, 25, 1658-1664 (2007) (Pubitemid 46797944)
112. Hecht, J. R., A. Patnaik, J. Berlin, A. Venook, I. Malik, S. Tchekmedyian, L. Navale, R. G. Amado & N. J. Meropol: Panitumumab monotherapy in patients with previously treated metastatic colorectal cancer. Cancer, 110, 980-988 (2007) (Pubitemid 47312862)
113. Siena, S., J. Tabernero, R. L. Burkes, J. Cassidy, D. Cunningham, M. E. Barugel, Y. Humblet, C. McPhie, M. Shing & J. Douillard: Phase III study (PRIME/20050203) of panitumumab (pmab) with FOLFOX compared with FOLFOX alone in patients (pts) with previously untreated metastatic colorectal cancer (mCRC): Pooled safety data. J Clin Oncol (Meeting Abstracts), 26, 4034- (2008)
114. Peeters, M., G. Wilson, M. Ducreux, A. Cervantes, T. Andre, Y. Hotko, F. Lordick, S. Collins, M. Shing & T. J. Price: Phase III study (20050181) of panitumumab (pmab) with FOLFIRI versus FOLFIRI alone as second-line treatment (tx) in patients (pts) with metastatic colorectal cancer (mCRC): Pooled safety results. J Clin Oncol (Meeting Abstracts), 26, 4064- (2008)
115. Li, S., P. Kussie & K. M. Ferguson: Structural basis for EGF receptor inhibition by the therapeutic antibody IMC- 11F8. Structure, 16, 216-27 (2008) (Pubitemid 351215209)
116. Kuenen, B., P. O. Witteveen, R. Ruijter, G. Giaccone, A. Dontabhaktuni, F. Fox, T. Katz, H. Youssoufian, J. Zhu, E. K. Rowinsky & E. E. Voest: A Phase I Pharmacologic Study of Necitumumab (IMC-11F8), a Fully Human IgG1 Monoclonal Antibody Directed Against EGFR in Patients with Advanced Solid Malignancies. Clinical Cancer Research, 16, 1915-1923 (2010)
117. Prewett, M., J. R. Tonra, B. Rajiv, A. T. Hooper, G. Makhoul, B. Finnerty, L. Witte, P. Bohlen, Z. Zhu & D. J. Hicklin: Antitumor activity of a novel, human anti-epidermal growth factor receptor (EGFR) monoclonal antibody (IMC- 11F8) in human tumor xenograft models. AACR Meeting Abstracts, 2004, 1235- (2004)
118. Cunningham, M. P., H. Thomas, Z. Fan & H. Modjtahedi: Responses of Human Colorectal Tumor Cells to Treatment with the Anti-Epidermal Growth Factor Receptor Monoclonal Antibody ICR62 Used Alone and in Combination with the EGFR Tyrosine Kinase Inhibitor Gefitinib. Cancer Research, 66, 7708-7715 (2006) (Pubitemid 44289230)
119. Modjtahedi, H. & C. Dean: Monoclonal antibodies to the EGF receptor act as betacellulin antagonists. Biochemical & Biophysical Research Communications, 221, 625-30 (1996) (Pubitemid 26160062)
120. Modjtahedi, H., S. A. Eccles, G. Box, J. Styles & C. J. Dean: Antitumor activity of combinations of antibodies directed against different epitopes on the extracellular domain of the human EGF receptor. Cell Biophysics, 22, 129-46 (1993)
121. Modjtahedi, H., D. K. Moscatello, G. Box, M. Green, C. Shoton, D. J. Lamb, L. J. Reynolds, A. J. Wong, C. Dean, H. Thomas & S. Eccles: Targeting of cells expressing wild-type EGFR and type-III mutant EGFR (EGFR VIII) by anti-EGFR MAB ICR62: A twopronged attack for tomour therapy. Internation Journal of Cancer, 105, 273-280 (2003) (Pubitemid 36505333)
122. Cohen, M. H., G. A. Williams, R. Sridhara, G. Chen & R. Pazer: FDA drug approval summary: Gefitinib (ZD1839) (Iressa) tablet. Oncologist, 8, 303-306 (2003) (Pubitemid 36929716)
123. Cohen, M. H., J. R. Johnson, Y.-F. Chen, R. Sridhara & R. Pazdur: FDA Drug Approval Summary: Erlotinib (Tarceva®) Tablets. The Oncologist, 10, 461- 466 (2005) (Pubitemid 41266326)
124. Vieitez, J. M., M. Valladares, I. Pelaez, L. de Sande Gonzalez, J. Garcia-Foncillas, J. L. Garcia-Lopez, C. Garcia-Giron, M. Reboredo, H. Bovio & A. J. Lacave: A randomized phase II study of raltitrexed and gefitinib versus raltitrexed alone as second line chemotherapy in patients with colorectal cancer. (1839IL/0143). Investigational New Drugs, 29, 1038-44 (2011)
125. Hartmann, J. T., J. P. Pintoffl, H. Kröning, C. Bokemeyer, M. Holtmann & T. Höhler: Gefitinib in Combination with Oxaliplatin and 5-Fluorouracil in Irinotecan-Refractory Patients with Colorectal Cancer: A Phase I Study of the Arbeits gemeinschaft Internistische Onkologie (AIO). Onkologie, 31, 237-241 (2008) (Pubitemid 351744823)
126. Fisher, G. A., T. Kuo, M. Ramsey, E. Schwartz, R. V. Rouse, C. D. Cho, J. Halsey & B. I. Sikic: A phase II study of gefitinib, 5-fluorouracil, leucovorin, and oxaliplatin in previously untreated patients with metastatic colorectal cancer. Clinical Cancer Research, 14, 7074-9 (2008)
127. Gelibter, A. J., T. Gamucci, C. F. Pollera, F. Di Costanzo, C. Nuzzo, A. Gabriele, C. Signorelli, S. Gasperoni, V. Ferraresi, D. Giannarelli, F. Cognetti & M. Zeuli: A phase II trial of gefitinib in combination with capecitabine and oxaliplatin as first-line chemotherapy in patients with advanced colorectal cancer. Current Medical Research & Opinion, 23, 2117-23 (2007) (Pubitemid 350246598)
128. Meyerhardt, J. A., J. W. Clark, J. G. Supko, J. P. Eder, S. Ogino, C. F. Stewart, F. D'Amato, J. Dancey, P. C. Enzinger, A. X. Zhu, D. P. Ryan, C. C. Earle, R. J. Mayer, A. Michelini, K. Kinsella & C. S. Fuchs: Phase I study of gefitinib, irinotecan, 5-fluorouracil and leucovorin in patients with metastatic colorectal cancer. Cancer Chemotherapy & Pharmacology, 60, 661-70 (2007) (Pubitemid 47247278)
129. Chau, I., D. Cunningham, T. Hickish, A. Massey, L. Higgins, R. Osborne, N. Botwood & A. Swaisland: Gefitinib and irinotecan in patients with fluoropyrimidinerefractory, irinotecan-naive advanced colorectal cancer: a phase I-II study. Annals of Oncologymdl481 (2007)
130. Hofheinz, R. D., S. Kubicka, J. Wollert, D. Arnold & A. Hochhaus: Gefitinib in combination with 5-fluorouracil (5-FU)/folinic acid and irinotecan in patients with 5- FU/oxaliplatin- refractory colorectal cancer: a phase I/II study of the Arbeitsgemeinschaft fur Internistische Onkologie (AIO). Onkologie, 29, 563-7 (2006) (Pubitemid 46005779)
131. Wolpin, B. M., J. W. Clark, J. A. Meyerhardt, C. C. Earle, D. P. Ryan, P. C. Enzinger, A. X. Zhu, L. Blaszkowsky, S. Battu & C. S. Fuchs: Phase I study of gefitinib plus FOLFIRI in previously untreated patients with metastatic colorectal cancer. Clinical Colorectal Cancer, 6, 208-13 (2006) (Pubitemid 44596770)
132. Kuo, T., C. D. Cho, J. Halsey, H. A. Wakelee, R. H. Advani, J. M. Ford, G. A. Fisher & B. I. Sikic: Phase II study of gefitinib, fluorouracil, leucovorin, and oxaliplatin therapy in previously treated patients with metastatic colorectal cancer. Journal of Clinical Oncology, 23, 5613-9 (2005)
133. Kindler, H. L., G. Friberg, L. Skoog, K. Wade-Oliver & E. E. Vokes: Phase I/II trial of gefitinib and oxaliplatin in patients with advanced colorectal cancer. American Journal of Clinical Oncology, 28, 340-4 (2005) (Pubitemid 41099537)
134. Rothenberg, M. L., B. LaFleur, D. E. Levy, M. K. Washington, S. L. Morgan-Meadows, R. K. Ramanathan, J. D. Berlin, A. B. Benson, III & R. J. Coffey: Randomized Phase II Trial of the Clinical and Biological Effects of Two Dose Levels of Gefitinib in Patients With Recurrent Colorectal Adenocarcinoma. J Clin Oncol, 23, 9265-9274 (2005)
135. Trarbach, T., A. Reinacher-Schick, S. Hegewisch- Becker, U. Vanhoefer, T. Frieling, L. Lehnert, W. Schmiegel & U. Graeven: Gefitinib in combination with capecitabine as second-line therapy in patients with advanced colorectal cancer (aCRC): a phase I/II study of the Arbeitsgemeinschaft Internistische Onkologie (AIO). Onkologie, 33, 89-93 (2010)
136. Santoro, A., A. Comandone, L. Rimassa, C. Granetti, V. Lorusso, C. Oliva, M. Ronzoni, S. Siena, M. Zuradelli, E. Mari, T. Pressiani & C. Carnaghi: A phase II randomized multicenter trial of gefitinib plus FOLFIRI and FOLFIRI alone in patients with metastatic colorectal cancer. Annals of Oncology, 19, 1888-1893 (2008)
137. Jimeno, A., C. Grávalos, P. Escudero, I. Sevilla, M. Vega-Villegas, V. Alonso, I. Juez, R. García-Carbonero, H. Bovio, R. Colomer & H. Cortés-Funes: Phase I/II study of gefitinib and capecitabine in patients with colorectal cancer. Clinical & Translational Oncology, 10, 52-57 (2008)
138. Stebbing, J., M. Harrison, R. Glynne-Jones, J. Bridgewater & D. Propper: A phase II study to determine the ability of gefitinib to reverse fluoropyrimidine resistance in metastatic colorectal cancer (the INFORM study). British Journal of Cancer, 98, 716-9 (2008) (Pubitemid 351272618)
139. Kelley, R. K. & A. H. Ko: Erlotinib in the treatment of advanced pancreatic cancer. Biologics, 2, 83-95 (2008)
140. Hidalgo, M., L. L. Siu, J. Nemunaitis, J. Rizzo, L. A. Hammond, C. Takimoto, S. G. Eckhardt, A. Tolcher, C. D. Britten, L. Denis, K. Ferrante, D. D. Von Hoff, S. Silberman & E. K. Rowinsky: Phase I and Pharmacologic Study of OSI-774, an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, in Patients With Advanced Solid Malignancies. J Clin Oncol, 19, 3267-3279 (2001) (Pubitemid 32591445)
141. Keilholz, U., D. Arnold, N. Niederle, W. Freier, R. Porschen, T. Hoehler, F. Lordick, S. Kubicka, E. Kettner & H.-J. Schmoll: Erlotinib as 2nd and 3rd line monotherapy in patients with metastatic colorectal cancer. Results of a multicenter two-cohort phase II trial. J Clin Oncol (Meeting Abstracts), 23, 3575- (2005)
142. Meyerhardt, J. A., A. X. Zhu, P. C. Enzinger, D. P. Ryan, J. W. Clark, M. H. Kulke, C. C. Earle, M. Vincitore, A. Michelini, S. Sheehan & C. S. Fuchs: Phase II study of capecitabine, oxaliplatin, and erlotinib in previously treated patients with metastastic colorectal cancer. Journal of Clinical Oncology, 24, 1892-7 (2006)
143. Messersmith, W. A., A. Jimeno, H. Jacene, M. Zhao, P. Kulesza, D. A. Laheru, Y. Kahn, A. Spira, J. Dancey, C. Iacobuzio-Donahue, R. C. Donehower, M. Carducci, M. A. Rudek & M. Hidalgo: Phase I trial of oxaliplatin, infusional 5-fluorouracil, and leucovorin (FOLFOX4) with erlotinib and bevacizumab in colorectal cancer. Clinical Colorectal Cancer, 9, 297- 304 (2010)
144. Weickhardt, A. J., T. J. Price, G. Chong, V. Gebski, N. Pavlakis, T. G. Johns, A. Azad, E. Skrinos, K. Fluck, A. Dobrovic, R. Salemi, A. M. Scott, J. M. Mariadason & N. C. Tebbutt: Dual Targeting of the Epidermal Growth Factor Receptor Using the Combination of Cetuximab and Erlotinib: Preclinical Evaluation and Results of the Phase II DUX Study in Chemotherapy- Refractory, Advanced Colorectal Cancer. Journal of Clinical Oncology (2012)
145. Kuwada, S. K., C. L. Scaife, J. Kuang, X. Li, R. F. Wong, S. R. Florell, R. J. Coffey & P. D. Gray: Effects of trastuzumab on epidermal growth factor receptor dependent and -independent human colon cancer cells. International Journal of Cancer, 109, 291-301 (2004) (Pubitemid 38240934)
146. Sorscher, S. M.: Marked response to single agent trastuzumab in a patient with metastatic HER-2 gene amplified rectal cancer. Cancer Investigation, 29, 456-9 (2011)
147. Scartozzi, M., R. Giampieri, E. Maccaroni, A. Mandolesi, L. Giustini, R. Silva, A. Zaniboni, T. Biscotti, S. Biagetti, E. Galizia, F. Loupakis, A. Falcone, I. Bearzi & S. Cascinu: Analysis of HER-3, insulin growth factor-1, nuclear factor-kB and epidermal growth factor receptor gene copy number in the prediction of clinical outcome for K-RAS wild-type colorectal cancer patients receiving irinotecan-cetuximab. Annals of Oncology (2011)
148. Engelman, J. A., P. A. Janne, C. Mermel, J. Pearlberg, T. Mukohara, C. Fleet, K. Cichowski, B. E. Johnson & L. C. Cantley: ErbB-3 mediates phosphoinositide 3-kinase activity in gefitinib-sensitive non-small cell lung cancer cell lines. Proceedings of the National Academy of Sciences of the United States of America, 102, 3788-93 (2005) (Pubitemid 40354690)
149. Engelman, J. A., K. Zejnullahu, T. Mitsudomi, Y. Song, C. Hyland, J. O. Park, N. Lindeman, C. M. Gale, X. Zhao, J. Christensen, T. Kosaka, A. J. Holmes, A. M. Rogers, F. Cappuzzo, T. Mok, C. Lee, B. E. Johnson, L. C. Cantley & P. A. Janne: MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science, 316, 1039-43 (2007) (Pubitemid 46799492)
150. Schoeberl, B., E. A. Pace, J. B. Fitzgerald, B. D. Harms, L. Xu, L. Nie, B. Linggi, A. Kalra, V. Paragas, R. Bukhalid, V. Grantcharova, N. Kohli, K. A. West, M. Leszczyniecka, M. J. Feldhaus, A. J. Kudla & U. B. Nielsen: Therapeutically Targeting ErbB3: A Key Node in Ligand-Induced Activation of the ErbB Receptor-PI3K Axis. Sci. Signal., 2, ra31- (2009)
151. Sheng, Q., X. Liu, E. Fleming, K. Yuan, H. Piao, J. Chen, Z. Moustafa, R. K. Thomas, H. Greulich, A. Schinzel, S. Zaghlul, D. Batt, S. Ettenberg, M. Meyerson, B. Schoeberl, A. L. Kung, W. C. Hahn, R. Drapkin, D. M. Livingston & J. F. Liu: An Activated ErbB3/NRG1 Autocrine Loop Supports In vivo Proliferation in Ovarian Cancer Cells. Cancer Cell, 17, 298-310 (2010)
152. Geyer, C. E., J. Forster, D. Lindquist, S. Chan, C. G. Romieu, T. Pienkowski, A. Jagiello-Gruszfeld, J. Crown, A. Chan, B. Kaufman, D. Skarlos, M. Campone, N. Davidson, M. Berger, C. Oliva, S. D. Rubin, S. Stein & D. Cameron: Lapatinib plus Capecitabine for HER2-Positive Advanced Breast Cancer. N Engl J Med, 355, 2733-2743 (2006) (Pubitemid 46021510)
153. LaBonte, M. J., P. C. Manegold, P. M. Wilson, W. Fazzone, S. G. Louie, H.-J. Lenz & R. D. Ladner: The dual EGFR/HER-2 tyrosine kinase inhibitor lapatinib sensitizes colon and gastric cancer cells to the irinotecan active metabolite SN-38. International Journal of Cancer, 125, 2957-2969 (2009)
154. Kim, H. P., Y. K. Yoon, J. W. Kim, S. W. Han, H. S. Hur, J. Park, J. H. Lee, D. Y. Oh, S. A. Im, Y. J. Bang & T. Y. Kim: Lapatinib, a dual EGFR and HER2 tyrosine kinase inhibitor, downregulates thymidylate synthase by inhibiting the nuclear translocation of EGFR and HER2. PLoS ONE, 4, e5933 (2009)
155. Solca, F.: Pharmacology and molecular mechanisms of BIBW2992 a potent irreversible dual EGFR/HER-2 kinase inhibitor of cancer therapy. Targeted Oncology, 2, S15 (2007)
156. Eskens, F. A. L. M., C. H. Mom, A. S. T. Planting, J. A. Gietema, A. Amelsberg, H. Huisman, L. van Doorn, H. Burger, P. Stopfer, J. Verweij & E. G. E. de Vries: A phase I dose escalation study of BIBW 2992, an irreversible dual inhibitor of epidermal growth factor receptor 1 (EGFR) and 2 (HER2) tyrosine kinase in a 2- week on, 2-week off schedule in patients with advanced solid tumours. British Journal of Cancer, 98, 80-85 (2007)
157. Minkovsky, N. & A. Berezov: BIBW-2992, a dual receptor tyrosine kinase inhibitor for the treatment of solid tumors. Curr Opin Investig Drugs, 9, 1336-46 (2008)
158. Bouche, O., M. Ducreux, G. Lledo, T. Andre, F. Maindrault-Goebel, P. Stopfer, Z. Oum'Hamed, M. Chadjaa & A. de Gramont: A Phase II Trial of Weekly Alternating Sequential Administration of BIBF 1120 and BIBW 2992 in Patients With Advanced Colorectal Cancer. J Clin Oncol, 26, (2008)
159. Yap, T. A., L. Vidal, J. Adam, P. Stephens, J. Spicer, H. Shaw, J. Ang, G. Temple, S. Bell, M. Shahidi, M. Uttenreuther-Fischer, P. Stopfer, A. Futreal, H. Calvert, J. S. de Bono & R. Plummer: Phase I Trial of the Irreversible EGFR and HER2 Kinase Inhibitor BIBW 2992 in Patients With Advanced Solid Tumors. J Clin Oncol, 28, 3965-3972 (2010)
160. Nam, H.-J., H.-P. Kim, Y.-K. Yoon, H.-S. Hur, S.- H. Song, M.-S. Kim, G.-S. Lee, S.-W. Han, S.-A. Im & T.-Y. Kim: Antitumor activity of HM781-36B, an irreversible Pan-HER inhibitor, alone or in combination with cytotoxic chemotherapeutic agents in gastric cancer. Cancer Letters, 302, 155-165 (2011)
161. Cha, M. Y., K. O. Lee, M. Kim, J. Y. Song, K. H. Lee, J. Park, Y. J. Chae, Y. H. Kim, K. H. Suh, G. S. Lee, S. B. Park & M. S. Kim: Antitumor activity of HM781-36B, a highly effective pan-HER inhibitor in erlotinib-resistant NSCLC and other EGFR-dependent cancer models. International Journal of Cancer, 130, 2445-54 (2012)
162. Wong, T. W., F. Y. Lee, C. Yu, F. R. Luo, S. Oppenheimer, H. Zhang, R. A. Smykla, H. Mastalerz, B. E. Fink, J. T. Hunt, A. V. Gavai & G. D. Vite: Preclinical antitumor activity of BMS-599626, a pan-HER kinase inhibitor that inhibits HER1/HER2 homodimer and heterodimer signaling. Clinical Cancer Research, 12, 6186-93 (2006) (Pubitemid 44703785)
163. Laheru, D., G. Croghan, R. Bukowski, M. Rudek, W. Messersmith, C. Erlichman, R. Pelley, A. Jimeno, R. Donehower, J. Boni, R. Abbas, P. Martins, C. Zacharchuk & M. Hidalgo: A phase I study of EKB-569 in combination with capecitabine in patients with advanced colorectal cancer. Clinical Cancer Research, 14, 5602-9 (2008)
164. McDonagh, C. F., A. Huhalov, B. D. Harms, S. Adams, V. Paragas, S. Oyama, B. Zhang, L. Luus, R. Overland, S. Nguyen, J. Gu, N. Kohli, M. Wallace, M. J. Feldhaus, A. J. Kudla, B. Schoeberl & U. B. Nielsen: Antitumor Activity of a Novel Bispecific Antibody That Targets the ErbB2/ErbB3 Oncogenic Unit and Inhibits Heregulin-Induced Activation of ErbB3. Molecular Cancer Therapeutics, 11, 582-93 (2012)
165. Siena, S., A. Sartore-Bianchi, F. Di Nicolantonio, J. Balfour & A. Bardelli: Biomarkers predicting clinical outcome of epidermal growth factor receptor-targeted therapy in metastatic colorectal cancer. Journal of the National Cancer Institute, 101, 1308-24 (2009)
166. Saltz, L. B., N. J. Meropol, P. J. Loehrer, Sr, M. N. Needle, J. Kopit & R. J. Mayer: Phase II Trial of Cetuximab in Patients With Refractory Colorectal Cancer That Expresses the Epidermal Growth Factor Receptor. J Clin Oncol, 22, 1201-1208 (2004) (Pubitemid 41079832)
167. Hecht, J. R., E. Mitchell, M. A. Neubauer, H. A. Burris Iii, P. Swanson, T. Lopez, G. Buchanan, M. Reiner, J. Gansert & J. Berlin: Lack of correlation between epidermal growth factor receptor status and response to panitumumab monotherapy in metastatic colorectal cancer. Clinical Cancer Research, 16, 2205-2213 (2010)
168. Han, H.-S., H. J. Chang, Y. S. Hong, S. Y. Kim, K. S. Lee & K. H. Jung: Epidermal Growth Factor Receptor Expression Discrepancies in Metastatic Colorectal Cancer Patients Treated with Cetuximab Plus Irinotecan-Based Chemotherapy Refractory to Irinotecan and Oxaliplatin. Diseases of the Colon & Rectum, 52, 1144-1151 (2009)
169. Yarom, N., C. Marginean, T. Moyana, I. Gorn- Hondermann, H. C. Birnboim, H. Marginean, R. C. Auer, M. Vickers, T. R. Asmis, J. Maroun & D. Jonker: EGFR expression variance in paired colorectal cancer primary and metastatic tumors. Cancer Biology & Therapy, 10, 416-421 (2010)
170. Bralet, M. P., B. Paule, B. Falissard, R. Adam & C. Guettier: Immunohistochemical variability of epidermal growth factor receptor (EGFR) in liver metastases from clonic carcinomas. Histopathology, 50, 210-216 (2007) (Pubitemid 46046389)
171. Amin, D. N., K. Hida, D. R. Bielenberg & M. Klagsbrun: Tumor endothelial cells express epidermal growth factor receptor (EGFR) but not ErbB3 and are responsive to EGF and to EGFR kinase inhibitors. Cancer Research, 66, 2173-80 (2006)
172. Won, Y.-W., J.-Y. Han, G. K. Lee, S.-Y. Park, K. Y. Lim, K.-A. Yoon, T. Yun, H. T. Kim & J. S. Lee: Comparison of clinical outcome of patients with nonsmall- cell lung cancer harbouring epidermal growth factor receptor exon 19 or exon 21 mutations. Journal of Clinical Pathology, 64, 947-952 (2011)
173. Martínez-Navarro, E., J. Rebollo, R. González- Manzano, M. Sureda, E. Evgenyeva, B. Valenzuela, F. Fernández, J. Forteza & A. Brugarolas: Epidermal growth factor receptor (EGFR) mutations in a series of non-small-cell lung cancer (NSCLC) patients and response rate to EGFR-specific tyrosine kinase inhibitors (TKIs). Clinical & Translational Oncology, 13, 812-818 (2011)
174. Ma, C., S. Wei & Y. Song: T790M and acquired resistance of EGFR TKI: a literature review of clinical reports. J Thorac Dis, 3, 10-8 (2011)
175. Lee, J. W., Y. H. Soung, S. Y. Kim, W. S. Park, S. W. Nam, J. Y. Lee, N. J. Yoo & S. H. Lee: Absence of EGFR mutation in the kinase domain in common human cancers besides non-small cell lung cancer. International Journal of Cancer, 113, 510-1 (2005) (Pubitemid 40038725)
176. Barber, T. D., B. Vogelstein, K. W. Kinzler & V. E. Velculescu: Somatic mutations of EGFR in colorectal cancers and glioblastomas. New England Journal of Medicine, 351, 2883 (2004) (Pubitemid 40051921)
177. Montagut, C., A. Dalmases, B. Bellosillo, M. Crespo, S. Pairet, M. Iglesias, M. Salido, M. Gallen, S. Marsters, S. P. Tsai, A. Minoche, S. Somasekar, S. Serrano, H. Himmelbauer, J. Bellmunt, A. Rovira, J. Settleman, F. Bosch & J. Albanell: Identification of a mutation in the extracellular domain of the Epidermal Growth Factor Receptor conferring cetuximab resistance in colorectal cancer. Nature Medicine, 18, 221-3 (2012)
178. Cappuzzo, F., G. Finocchiaro, E. Rossi, P. A. Janne, C. Carnaghi, C. Calandri, K. Bencardino, C. Ligorio, F. Ciardiello, T. Pressiani, A. Destro, M. Roncalli, L. Crino, W. A. Franklin, A. Santoro & M. Varella-Garcia: EGFR FISH assay predicts for response to cetuximab in chemotherapy refractory colorectal cancer patients. Annals of Oncology, 19, 717-23 (2008) (Pubitemid 351461042)
179. Personeni, N., S. Fieuws, H. Piessevaux, G. De Hertogh, J. De Schutter, B. Biesmans, W. De Roock, A. Capoen, M. Debiec-Rychter, J. L. Van Laethem, M. Peeters, Y. Humblet, E. Van Cutsem & S. Tejpar: Clinical usefulness of EGFR gene copy number as a predictive marker in colorectal cancer patients treated with cetuximab: a fluorescent in situ hybridization study. Clinical Cancer Research, 14, 5869-76 (2008)
180. Algars, A., M. Lintunen, O. Carpen, R. Ristamaki & J. Sundstrom: EGFR gene copy number assessment from areas with highest EGFR expression predicts response to anti-EGFR therapy in colorectal cancer. British Journal of Cancer, 105, 255-262 (2011)
181. Jacobs, B., W. De Roock, H. Piessevaux, R. Van Oirbeek, B. Biesmans, J. De Schutter, S. Fieuws, J. Vandesompele, M. Peeters, J. L. Van Laethem, Y. Humblet, F. Penault-Llorca, G. De Hertogh, P. Laurent- Puig, E. Van Cutsem & S. Tejpar: Amphiregulin and epiregulin mRNA expression in primary tumors predicts outcome in metastatic colorectal cancer treated with cetuximab. Journal of Clinical Oncology, 27, 5068-74 (2009)
182. Saridaki, Z., M. Tzardi, C. Papadaki, M. Sfakianaki, F. Pega, A. Kalikaki, E. Tsakalaki, M. Trypaki, I. Messaritakis, E. Stathopoulos, D. Mavroudis, V. Georgoulias & J. Souglakos: Impact of KRAS, BRAF, PIK3CA mutations, PTEN, AREG, EREG expression and skin rash in 2 line cetuximab-based therapy of colorectal cancer patients. PLoS ONE, 6, e15980 (2011)
183. Di Fiore, F., R. Sesboue, P. Michel, J. C. Sabourin & T. Frebourg: Molecular determinants of anti-EGFR sensitivity and resistance in metastatic colorectal cancer. Br J Cancer, 103, 1765-1772 (2010)
184. Lievre, A., J.-B. Bachet, V. Boige, A. Cayre, D. Le Corre, E. Buc, M. Ychou, O. Bouche, B. Landi, C. Louvet, T. Andre, F. Bibeau, M.-D. Diebold, P. Rougier, M. Ducreux, G. Tomasic, J.-F. Emile, F. Penault-Llorca & P. Laurent-Puig: KRAS Mutations As an Independent Prognostic Factor in Patients With Advanced Colorectal Cancer Treated With Cetuximab. J Clin Oncol, 26, 374-379 (2008) (Pubitemid 351171687)
185. Yen, L. C., Y. H. Uen, D. C. Wu, C. Y. Lu, F. J. Yu, I. C. Wu, S. R. Lin & J. Y. Wang: Activating KRAS Mutations and Overexpression of Epidermal Growth Factor Receptor as Independent Predictors in Metastatic Colorectal Cancer Patients Treated With Cetuximab. Annals of Surgery, 251, 254-260 (2010)
186. Roth, A. D., S. Tejpar, M. Delorenzi, P. Yan, R. Fiocca, D. Klingbiel, D. Dietrich, B. Biesmans, G. Bodoky, C. Barone, E. Aranda, B. Nordlinger, L. Cisar, R. Labianca, D. Cunningham, E. Van Cutsem & F. Bosman: Prognostic Role of KRAS and BRAF in Stage II and III Resected Colon Cancer: Results of the Translational Study on the PETACC-3, EORTC 40993, SAKK 60-00 Trial. J Clin Oncol, 28, 466-474 (2010)
187. Lievre, A., J.-B. Bachet, D. Le Corre, V. Boige, B. Landi, J.-F. Emile, J.-F. Cote, G. Tomasic, C. Penna, M. Ducreux, P. Rougier, F. Penault-Llorca & P. Laurent-Puig: KRAS Mutation Status Is Predictive of Response to Cetuximab Therapy in Colorectal Cancer. Cancer Res, 66, 3992-3995 (2006)
188. Amado, R. G., M. Wolf, M. Peeters, E. Van Cutsem, S. Siena, D. J. Freeman, T. Juan, R. Sikorski, S. Suggs, R. Radinsky, S. D. Patterson & D. D. Chang: Wild-Type KRAS Is Required for Panitumumab Efficacy in Patients With Metastatic Colorectal Cancer. J Clin Oncol, 26, 1626- 1634 (2008)
189. Allegra, C. J., J. M. Jessup, M. R. Somerfield, S. R. Hamilton, E. H. Hammond, D. F. Hayes, P. K. McAllister, R. F. Morton & R. L. Schilsky: American Society of Clinical Oncology Provisional Clinical Opinion: Testing for KRAS Gene Mutations in Patients With Metastatic Colorectal Carcinoma to Predict Response to Anti- Epidermal Growth Factor Receptor Monoclonal Antibody Therapy. J Clin Oncol, 27, 2091-2096 (2009)
190. Tol, J., M. Koopman, A. Cats, C. J. Rodenburg, G. J. Creemers, J. G. Schrama, F. L. Erdkamp, A. H. Vos, C. J. van Groeningen, H. A. Sinnige, D. J. Richel, E. E. Voest, J. R. Dijkstra, M. E. Vink-Borger, N. F. Antonini, L. Mol, J. H. van Krieken, O. Dalesio & C. J. Punt: Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer. New England Journal of Medicine, 360, 563-72 (2009)
191. Stintzing, S., L. Fischer von Weikersthal, T. Decker, U. Vehling-Kaiser, E. Jager, T. Heintges, C. Stoll, C. Giessen, D. P. Modest, J. Neumann, A. Jung, T. Kirchner, W. Scheithauer & V. Heinemann: FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer-subgroup analysis of patients with KRAS: mutated tumours in the randomised German AIO study KRK-0306. Annals of Oncology (2012)
192. Di Nicolantonio, F., M. Martini, F. Molinari, A. Sartore-Bianchi, S. Arena, P. Saletti, S. De Dosso, L. Mazzucchelli, M. Frattini, S. Siena & A. Bardelli: Wild- Type BRAF Is Required for Response to Panitumumab or Cetuximab in Metastatic Colorectal Cancer. J Clin Oncol, 26, 5705-5712 (2008)
193. Yokota, T.: Are KRAS/BRAF mutations potent prognostic and/or predictive biomarkers in colorectal cancers? Anti-Cancer Agents in Medicinal Chemistry, 12, 163-71 (2012)
194. Nosho, K., T. Kawasaki, M. Ohnishi, Y. Suemoto, G. J. Kirkner, D. Zepf, L. Yan, J. A. Longtine, C. S. Fuchs & S. Ogino: PIK3CA mutation in colorectal cancer: relationship with genetic and epigenetic alterations. Neoplasia, 10, 534-41 (2008) (Pubitemid 351770297)
195. Barault, L., N. Veyrie, V. Jooste, D. Lecorre, C. Chapusot, J. M. Ferraz, A. Lievre, M. Cortet, A. M. Bouvier, P. Rat, P. Roignot, J. Faivre, P. Laurent-Puig & F. Piard: Mutations in the RAS-MAPK, PI(3)K (phosphatidylinositol-3-OH kinase) signaling network correlate with poor survival in a population-based series of colon cancers. International Journal of Cancer, 122, 2255- 9 (2008)
196. Sartore-Bianchi, A., M. Martini, F. Molinari, S. Veronese, M. Nichelatti, S. Artale, F. Di Nicolantonio, P. Saletti, S. De Dosso, L. Mazzucchelli, M. Frattini, S. Siena & A. Bardelli: PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies. Cancer Research, 69, 1851-7 (2009)
197. De Roock, W., B. Claes, D. Bernasconi, J. De Schutter, B. Biesmans, G. Fountzilas, K. T. Kalogeras, V. Kotoula, D. Papamichael, P. Laurent-Puig, F. Penault-Llorca, P. Rougier, B. Vincenzi, D. Santini, G. Tonini, F. Cappuzzo, M. Frattini, F. Molinari, P. Saletti, S. De Dosso, M. Martini, A. Bardelli, S. Siena, A. Sartore-Bianchi, J. Tabernero, T. Macarulla, F. Di Fiore, A. O. Gangloff, F. Ciardiello, P. Pfeiffer, C. Qvortrup, T. P. Hansen, E. Van Cutsem, H. Piessevaux, D. Lambrechts, M. Delorenzi & S. Tejpar: Effects of KRAS, BRAF, NRAS, and PIK3CAmutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. The Lancet Oncology, 11, 753-762 (2010)
198. Prenen, H., J. De Schutter, B. Jacobs, W. De Roock, B. Biesmans, B. Claes, D. Lambrechts, E. Van Cutsem & S. Tejpar: PIK3CA mutations are not a major determinant of resistance to the epidermal growth factor receptor inhibitor cetuximab in metastatic colorectal cancer. Clinical Cancer Research, 15, 3184-8 (2009)
199. Nagata, Y., K. H. Lan, X. Zhou, M. Tan, F. J. Esteva, A. A. Sahin, K. S. Klos, P. Li, B. P. Monia, N. T. Nguyen, G. N. Hortobagyi, M. C. Hung & D. Yu: PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. Cancer Cell, 6, 117-27 (2004) (Pubitemid 39485684)
200. Stambolic, V., A. Suzuki, J. L. de la Pompa, G. M. Brothers, C. Mirtsos, T. Sasaki, J. Ruland, J. M. Penninger, D. P. Siderovski & T. W. Mak: Negative regulation of PKB/Aktdependent cell survival by the tumor suppressor PTEN. Cell, 95, 29-39 (1998) (Pubitemid 28458022)
201. Loupakis, F., L. Pollina, I. Stasi, A. Ruzzo, M. Scartozzi, D. Santini, G. Masi, F. Graziano, C. Cremolini, E. Rulli, E. Canestrari, N. Funel, G. Schiavon, I. Petrini, M. Magnani, G. Tonini, D. Campani, I. Floriani, S. Cascinu & A. Falcone: PTEN expression and KRAS mutations on primary tumors and metastases in the prediction of benefit from cetuximab plus irinotecan for patients with metastatic colorectal cancer. Journal of Clinical Oncology, 27, 2622-9 (2009)
202. Negri, F. V., C. Bozzetti, C. A. Lagrasta, P. Crafa, M. P. Bonasoni, R. Camisa, G. Pedrazzi & A. Ardizzoni: PTEN status in advanced colorectal cancer treated with cetuximab. British Journal of Cancer, 102, 162-164 (2010)
203. Park, J. H., S. W. Han, D. Y. Oh, S. A. Im, S. Y. Jeong, K. J. Park, T. Y. Kim, Y. J. Bang & J. G. Park: Analysis of KRAS, BRAF, PTEN, IGF1R, EGFR intron 1 CA status in both primary tumors and paired metastases in determining benefit from cetuximab therapy in colon cancer. Cancer Chemotherapy & Pharmacology1-11 (2011)
204. Dewaele, B., G. Floris, J. Finalet-Ferreiro, C. D. Fletcher, J. M. Coindre, L. Guillou, P. C. Hogendoorn, A. Wozniak, V. Vanspauwen, P. Schoffski, P. Marynen, P. Vandenberghe, R. Sciot & M. Debiec-Rychter: Coactivated platelet-derived growth factor receptor {alpha} and epidermal growth factor receptor are potential therapeutic targets in intimal sarcoma. Cancer Research, 70, 7304-14 (2010)
205. Krumbach, R., J. Schuler, M. Hofmann, T. Giesemann, H. H. Fiebig & T. Beckers: Primary resistance to cetuximab in a panel of patient-derived tumour xenograft models: activation of MET as one mechanism for drug resistance. European Journal of Cancer, 47, 1231-43 (2011)
206. Peters, G., S. Gongoll, C. Langner, M. Mengel, P. Piso, J. Klempnauer, J. Rüschoff, H. Kreipe & R. von Wasielewski: IGF-1R, IGF-1 and IGF-2 expression as potential prognostic and predictive markers in colorectalcancer. Virchows Archiv, 443, 139-145 (2003) (Pubitemid 37056137)
207. Weber, M. M., C. Fottner, S. B. Liu, M. C. Jung, D. Engelhardt & G. B. Baretton: Overexpression of the insulin-like growth factor I receptor in human colon carcinomas. Cancer, 95, 2086-2095 (2002) (Pubitemid 35253369)
208. Ouban, A., P. Muraca, T. Yeatman & D. Coppola: Expression and distribution of insulin-like growth factor-1 receptor in human carcinomas. Human Pathology, 34, 803- 808 (2003) (Pubitemid 37040618)
209. Scartozzi, M., A. Mandolesi, R. Giampieri, C. Pierantoni, F. Loupakis, A. Zaniboni, E. Galizia, L. Giustini, R. R. Silva, R. Bisonni, R. Berardi, S. Biagetti, S. Menzo, A. Falcone, I. Bearzi & S. Cascinu: Insulin-like growth factor 1 expression correlates with clinical outcome in K-RAS wild type colorectal cancer patients treated with cetuximab and irinotecan. International Journal of Cancer, 127, 1941-1947 (2010)
210. Hurbin, A., M. Wislez, B. Busser, M. Antoine, C. Tenaud, N. Rabbe, S. Dufort, F. de Fraipont, D. Moro- Sibilot, J. Cadranel, J. L. Coll & E. Brambilla: Insulin-like growth factor-1 receptor inhibition overcomes gefitinib resistance in mucinous lung adenocarcinoma. Journal of Pathology, 225, 83-95 (2011)
211. Cunningham, M. P., H. Thomas, C. Marks, M. Green, Z. Fan & H. Modjtahedi: Co-targeting the EGFR and IGRIR with anti-EGFR monoclonal antibody ICR62 and the IGF-IR tyrosine kinase inhibitor NVP-AEW541 in colorectal cancer cells. International Journal of Oncology, 33, 1107-1113 (2008)
212. Haluska, P., J. M. Carboni, D. A. Loegering, F. Y. Lee, M. Wittman, M. G. Saulnier, D. B. Frennesson, K. R. Kalli, C. A. Conover, R. M. Attar, S. H. Kaufmann, M. Gottardis & C. Erlichman: In vitro and in vivo antitumor effects of the dual insulin-like growth factor-I/insulin receptor inhibitor, BMS-554417. Cancer Research, 66, 362-71 (2006) (Pubitemid 43166043)
213. Haluska, P., J. M. Carboni, C. TenEyck, R. M. Attar, X. Hou, C. Yu, M. Sagar, T. W. Wong, M. M. Gottardis & C. Erlichman: HER receptor signaling confers resistance to the insulin-like growth factor-I receptor inhibitor, BMS- 536924.Molecular Cancer Therapeutics, 7, 2589-98 (2008)
214. Goetsch, L., A. Gonzalez, O. Leger, A. Beck, P. J. Pauwels, J. F. Haeuw & N. Corvaia: A recombinant humanized anti-insulin-like growth factor receptor type I antibody (h7C10) enhances the antitumor activity of vinorelbine and anti-epidermal growth factor receptor therapy against human cancer xenografts. International Journal of Cancer, 113, 316-28 (2005) (Pubitemid 39628325)
215. Dong, J., A. Sereno, D. Aivazian, E. Langley, B. R. Miller, W. B. Snyder, E. Chan, M. Cantele, R. Morena, I. B. Joseph, A. Boccia, C. Virata, J. Gamez, G. Yco, M. Favis, X. Wu, C. P. Graff, Q. Wang, E. Rohde, R. Rennard, L. Berquist, F. Huang, Y. Zhang, S. X. Gao, S. N. Ho, S. J. Demarest, M. E. Reff, K. Hariharan & S. M. Glaser: A stable IgG-like bispecific antibody targeting the epidermal growth factor receptor and the type I insulin-like growth factor receptor demonstrates superior anti-tumor activity. mAbs, 3, 273- 88 (2011)
216. Goldstein, N. S. & M. Armin: Epidermal growth factor receptor immunohistochemical reactivity in patients with American Joint Committee on Cancer Stage IV colon adenocarcinoma: implications for a standardized scoring system. Cancer, 92, 1331-46 (2001)
217. Italiano, A., M. C. Saint-Paul, F. X. Caroli-Bosc, E. Francois, A. Bourgeon, D. Benchimol, J. Gugenheim & J. F. Michiels: Epidermal growth factor receptor (EGFR) status in primary colorectal tumors correlates with EGFR expression in related metastatic sites: biological and clinical implications. Ann Oncol, 16, 1503-7 (2005)
218. Sauer, T., M. G. Guren, T. Noren & S. Dueland: Demonstration of EGFR gene copy loss in colorectal carcinomas by fluorescence in situ hybridization (FISH): a surrogate marker for sensitivity to specific anti-EGFR therapy? Histopathology, 47, 560-564 (2005) (Pubitemid 41775177)
219. Bibeau, F., F. Boissiere-Michot, J. C. Sabourin, S. Gourgou-Bourgade, M. Radal, F. Penault-Llorca, P. Rochaix, L. Arnould, M. P. Bralet, D. Azria & M. Ychou: Assessment of epidermal growth factor receptor (EGFR) expression in primary colorectal carcinomas and their related metastases on tissue sections and tissue microarray. Virchows Arch, 449, 281-7 (2006) (Pubitemid 44367967)
220. Theodorpoulos, G. E., E. Karafoka, j. G. Papailiou, p. Stamopoulos, c. P. Zambirinis, k. Bramis, s.-g. Panoussopoulos, e. Leandros & j. Bramis: p53 and EGFR Expression in Colorectal Cancer: A Reappraisal of 'Old' Tissue Markers in Patients with Long Follow-up. Anticancer Research, 29, 785-791 (2009)
221. Nathanson, D., A. Culliford, J. Shia, B. Chen, M. D'Alessio, Z. Zeng, G. Nash, W. Gerald, F. Barany & P. Paty: Her-2/neu expression and gene amplification in colon cancer. Int J Cancer, 105, 796 - 802 (2003) (Pubitemid 36706103)
222. Ramanathan, R. K., J. J. Hwang, W. C. Zamboni, F. A. Sinicrope, H. Safran, M. K. Wong, M. Earle, A. Brufsky, T. Evans, M. Troetschel, C. Walko, R. Day, H. X. Chen & S. Finkelstein: Low Overexpression of HER-2/Neu in Advanced Colorectal Cancer Limits the Usefulness of Trastuzumab (Herceptin®) and Irinotecan as Therapy. A Phase II Trial #, †. Cancer Investigation, 22, 858-865 (2004) (Pubitemid 39665350)
223. Herreros-Villanueva, M., M. Rodrigo, M. Claver, P. Muñiz, E. Lastra, C. García-Girón & M. J. Coma del Corral: KRAS, BRAF, EGFR and HER2 gene status in a Spanish population of colorectal cancer. Molecular Biology Reports (2010)
224. Ioannou, N., A. G. Dalgleish, A. M. Seddon, D. Mackintosh, U. Guertler, F. Solca & H. Modjtahedi: Antitumour activity of afatinib, an irreversible ErbB family blocker, in human pancreatic tumour cells. British Journal of Cancer, 105, 1554-62 (2011)
225. Modjtahedi, H., T. Hickish, M. Nicolson, J. Moore, J. Styles, S. Eccles, E. Jackson, J. Salter, J. Sloane, L. Spencer, K. Priest, I. Smith, C. Dean & M. Gore: Phase I trial and tumour localisation of the anti-EGFR monoclonal antibody ICR62 in head and neck or lung cancer. British Journal of Cancer, 73, 228-35 (1996) (Pubitemid 26029578)
226. Lacy, M. Q., M. Alsina, R. Fonseca, M. L. Paccagnella, C. L. Melvin, D. Yin, A. Sharma, M. Enriquez Sarano, M. Pollak, S. Jagannath, P. Richardson & A. Gualberto: Phase I, pharmacokinetic and pharmacodynamic study of the anti-insulinlike growth factor type 1 Receptor monoclonal antibody CP-751,871 in patients with multiple myeloma. Journal of Clinical Oncology, 26, 3196-203 (2008)
227. Watkins, D. J., J. Tabernero, H. J. Schmoll, T. Trarbach, F. J. Ramos, K. Hsu, M. Gates, J. Clark, P. LeVan & D. Cunningham: A phase II study of the anti- IGFR antibody MK-0646 in combination with cetuximab and irinotecan in the treatment of chemorefractory metastatic colorectal cancer. Journal of Clinical Oncology, 27, 4127- (2009)
228. Rowinsky, E. K., H. Youssoufian, J. R. Tonra, P. Solomon, D. Burtrum & D. L. Ludwig: IMC-A12, a human IgG1 monoclonal antibody to the insulin-like growth factor I receptor. Clinical Cancer Research, 13, 5549s-5555s (2007) (Pubitemid 47510386)
229. Slichenmyer, W. J., W. L. Elliott & D. W. Fry: CI- 1033, a pan-erbB tyrosine kinase inhibitor. Seminars in Oncology, 28, 80-5 (2001) (Pubitemid 33065113)
230. Garcia-Echeverria, C., M. A. Pearson & A. Marti: In vivo antitumor activity of NVP-AEW541 - A novel, potent and selective inhibitor of the IGF-IR kinase. Cancer Cell, 5, 231-239 (2004) (Pubitemid 38402115)
231. Oliveras-Ferraros, C., A. Vall-llovera, D. Salip, A. Vazquez-Martin, S. Cufí, B. Queralt, B. Martin-Castillo, J. Brunet, R. de Llorens & J. Menendez: Evolution of the predictive markers amphiregulin and epiregulin mRNAs during long-term cetuximab treatment of KRAS wild-type tumor cells. Investigational New Drugs, 30, 1-7 (2012)
232. Sos, M. L., M. Koker, B. A. Weir, S. Heynck, R. Rabinovsky, T. Zander, J. M. Seeger, J. Weiss, F. Fischer, P. Frommolt, K. Michel, M. Peifer, C. Mermel,
233. Cappuzzo, F.: EGFR FISH versus mutation: different tests, different end-points. Lung Cancer, 60, 160-5 (2008)
234. Takezawa, K., I. Okamoto, J. Tanizaki, K. Kuwata, H. Yamaguchi, M. Fukuoka, K. Nishio & K. Nakagawa: Enhanced anticancer effect of the combination of BIBW2992 and thymidylate synthase-targeted agents in non-small cell lung cancer with the T790M mutation of epidermal growth factor receptor. Molecular Cancer Therapeutics, 9, 1647-56 (2010)
235. Dahabreh, I. J., T. Terasawa, P. J. Castaldi & T. A. Trikalinos: Systematic review: Anti-epidermal growth factor receptor treatment effect modification by KRAS mutations in advanced colorectal cancer. Annals of Internal Medicine, 154, 37-49 (2011)
236. Jimeno, A., W. A. Messersmith, F. R. Hirsch, W. A. Franklin & S. G. Eckhardt: KRAS mutations and susceptibility to cetuximab and panitumumab in colorectal cancer. Cancer Journal, 15, 110-3 (2009)
237. Wang, L., Q. Zhang, J. Zhang, S. Sun, H. Guo, Z. Jia, B. Wang, Z. Shao, Z. Wang & X. Hu: PI3K pathway activation results in low efficacy of both trastuzumab and lapatinib. BMC Cancer, 11, 248 (2011)
238. Narayan, M., J. A. Wilken, L. N. Harris, A. T. Baron, K. D. Kimbler & N. J. Maihle: Trastuzumab-induced HER reprogramming in "resistant" breast carcinoma cells. Cancer Research, 69, 2191-4 (2009)